| Literature DB >> 24048296 |
Irene D Blackberry1, John S Furler, James D Best, Patty Chondros, Margarite Vale, Christine Walker, Trisha Dunning, Leonie Segal, James Dunbar, Ralph Audehm, Danny Liew, Doris Young.
Abstract
OBJECTIVE: To evaluate the effectiveness of goal focused telephone coaching by practice nurses in improving glycaemic control in patients with type 2 diabetes in Australia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24048296 PMCID: PMC3776648 DOI: 10.1136/bmj.f5272
Source DB: PubMed Journal: BMJ ISSN: 0959-8138

Flow of practices and patients through study
Baseline characteristics of practices, general practitioners, and patients with type 2 diabetes by study group. Values are numbers (column percentages) unless stated otherwise
| Characteristics | Total | Intervention group | Control group |
|---|---|---|---|
| Practices, No (row percentage) | 59 | 30 (51) | 29 (49) |
| Type of practice: | |||
| Private practice | 52 (88) | 26 (87) | 26 (90) |
| Corporate practice | 3 (5) | 2 (7) | 1 (3) |
| Community health centre | 4 (7) | 2 (7) | 2 (7) |
| Location of practice: | |||
| Urban | 25 (42) | 13 (43) | 12 (41) |
| Rural | 34 (58) | 17 (57) | 17 (59) |
| General practitioners: | |||
| 1 or 2 | 22 (37) | 12 (40) | 10 (35) |
| 3 or 4 | 28 (48) | 13 (43) | 15 (52) |
| 5-8 | 9 (15) | 5 (17) | 4 (14) |
| Practice nurses: | |||
| 1 | 49 (83) | 26 (87) | 23 (79) |
| 2 or 3 | 10 (17) | 4 (13) | 6 (21) |
| General practitioners*, No (row percentage): | 176 | 84 (48) | 92 (52) |
| Mean (SD) age (years)† | 48.2 (8.6) | 47.6 (8.3) | 48.6 (8.9) |
| Women | 55 (31) | 25 (30) | 30 (33) |
| Mean (SD) years of practice in Australia‡ | 19.8 (9.9) | 19.2 (9.8) | 20.3 (10.0) |
| Practice nurses, No (row percentage): | 70 | 34 (49) | 36 (51) |
| Women | 70 (100) | 34 (100) | 36 (100) |
| Patients§, No (row percentage): | 473 | 236 (50) | 237 (50) |
| Mean (SD) age at assessment (years) | 62.8 (10.5) | 63.6 (10.4) | 61.9 (10.5) |
| Women | 204 (43) | 109 (46) | 95 (40) |
| Highest level of education: | |||
| Primary or less | 100 (23) | 53 (24) | 47 (21) |
| Secondary or trade | 269 (61) | 139 (63) | 130 (59) |
| Tertiary | 73 (17) | 29 (13) | 44 (20) |
| Unemployed¶ | 35 (8) | 15 (7) | 20 (9) |
| Healthcare card holder | 277 (62) | 138 (61) | 139 (62) |
| Median (interquartile range) duration of diabetes (years) | 10 (5-14) | 10 (5-15) | 9 (5-13) |
| Diabetes complications: | |||
| Microvascular | 152 (33) | 78 (34) | 74 (33) |
| Macrovascular | 88 (19) | 37 (16) | 51 (23) |
*One general practitioner worked at two practices, both practices were allocated to control group; patients of this practitioner were recruited from only one practice.
†123 of 176 (70%) general practitioners provided their age; 56 in intervention group, 67 in control group.
‡115 of 176 (65%) general practitioners provided years they had practised in Australia; 48 in intervention group, 67 in control group.
§Discrepancies in totals owing to missing responses.
¶Unemployed compared with participants who were employed, had home duties, were retired, or other.
Biochemical, clinical, and psychosocial outcomes at baseline and 18 months by study group. Mean (standard deviations) are used for continuous outcomes and counts (proportions) for binary outcomes
| Outcomes | Intervention group | Control group | ICC* | Intervention effect (95% CI) | P value | |||
|---|---|---|---|---|---|---|---|---|
| No | Mean (SD)/No (%) | No | Mean (SD)/No (%) | |||||
| Serum HbA1c (%): | ||||||||
| Baseline | 235 | 7.98 (1.22) | 236 | 8.13 (1.34) | 0.098 | |||
| Follow-up | 221 | 7.85 (1.24) | 219 | 7.91 (1.42) | 0.02†§ (−0.20 to 0.24) | 0.84 | ||
| Total cholesterol (mmol/L): | ||||||||
| Baseline | 235 | 4.51 (1.04) | 230 | 4.50 (1.20) | 0.062 | |||
| Follow-up | 200 | 4.20 (0.95) | 200 | 4.28 (1.05) | −0.08† (−0.27 to 0.11) | 0.41 | ||
| Triglycerides (mmol/L): | ||||||||
| Baseline | 226 | 1.96 (1.61) | 225 | 2.07 (1.56) | 0.002 | |||
| Follow-up | 194 | 1.83 (1.39) | 197 | 1.92 (1.19) | −0.05†§ (−0.23 to 0.13) | 0.61 | ||
| Low density lipoprotein cholesterol (mmol/L): | ||||||||
| Baseline | 218 | 2.40 (0.89) | 208 | 2.40 (0.85) | 0.058 | |||
| Follow-up | 183 | 2.22 (0.87) | 183 | 2.26 (0.84) | 0.02† (−0.15 to 0.19) | 0.86 | ||
| High density lipoprotein cholesterol (mmol/L): | ||||||||
| Baseline | 222 | 1.22 (0.33) | 220 | 1.13 (0.31) | 0.051 | |||
| Follow-up | 187 | 1.21 (0.34) | 190 | 1.18 (0.31) | −0.05† (−0.09 to 0) | 0.05 | ||
| Normal ACR¶: | ||||||||
| Baseline | 214 | 153 (72) | 202 | 150 (74) | 0.008 | |||
| Follow-up | 175 | 125 (71) | 188 | 132 (70) | 1.05‡ (0.62 to 1.75) | 0.87 | ||
| Normal eGFR rate**: | ||||||||
| Baseline | 224 | 184 (82) | 203 | 169 (83) | — | |||
| Follow-up | 196 | 158 (81) | 201 | 165 (82) | 0.92‡§ (0.55 to 1.53) | 0.76 | ||
| Current smoker: | ||||||||
| Baseline | 235 | 30 (13) | 236 | 27 (11) | 0.043 | |||
| Follow-up | 187 | 25 (13) | 192 | 23 (12) | 1.14‡§ (0.55 to 2.36) | 0.72 | ||
| Healthy weight (BMI <25)††: | ||||||||
| Baseline | 233 | 22 (9) | 233 | 18 (14) | 0.024 | |||
| Follow-up | 189 | 26 (14) | 191 | 14 (7) | 2.19‡§ (1.10 to 4.38) | 0.03 | ||
| Weight (kg): | ||||||||
| Baseline | 234 | 91.0 (19.5) | 234 | 92.2 (20.5) | 0.059 | |||
| Follow-up | 189 | 90.7 (21.0) | 191 | 92.7 (21.0) | 0.12†§ (−1.53 to 1.77) | 0.89 | ||
| Men: | ||||||||
| Baseline | 121 | 109.7 (15.1) | 136 | 112.6 (14.8) | 0.063 | |||
| Follow-up | 94 | 110.0 (15.9) | 110 | 111.7 (15.0) | 0.90†§ (−1.40 to 3.19) | 0.44 | ||
| Women: | ||||||||
| Baseline | 105 | 106.1 (15.1) | 89 | 107.2 (15.5) | 0.062 | |||
| Follow-up | 81 | 105.3 (13.9) | 69 | 108.4 (15.5) | −1.52†§ (−4.08 to 1.04) | 0.24 | ||
| Systolic: | ||||||||
| Baseline | 234 | 139 (18) | 234 | 138 (18) | 0.096 | |||
| Follow-up | 189 | 133 (14) | 186 | 136 (16) | −3.17† (−6.55 to 0.22) | 0.07 | ||
| Diastolic: | ||||||||
| Baseline | 233 | 79 (10) | 234 | 79 (11) | 0.088 | |||
| Follow-up | 188 | 76 (9) | 186 | 77 (11) | 0.13† (−2.23 to 2.49) | 0.92 | ||
| Diabetes self efficacy36: | ||||||||
| Baseline | 202 | 78.57 (12.29) | 208 | 77.04 (12.98) | — | |||
| Follow-up | 175 | 81.23 (10.96) | 194 | 79.94 (11.46) | −0.06†§ (−2.22 to 2.10) | 0.96 | ||
| Diabetes support37: | ||||||||
| Baseline | 229 | 4.31 (0.46) | 231 | 4.28 (0.48) | 0.035 | |||
| Follow-up | 184 | 4.29 (0.48) | 197 | 4.22 (0.42) | 0.09† (−0.01 to 0.18) | 0.08 | ||
| Quality of life38: | ||||||||
| Baseline | 223 | 0.78 (0.18) | 231 | 0.78 (0.17) | — | |||
| Follow-up | 185 | 0.79 (0.17) | 197 | 0.77 (0.18) | 0.02† (−0.01 to 0.05) | 0.16 | ||
| Major depressive syndrome (PHQ-9)39: | ||||||||
| Baseline | 216 | 11 (5) | 220 | 11 (5) | 0.013 | |||
| Follow-up | 186 | 15 (8) | 195 | 14 (7) | 1.09‡ (0.49 to 2.46) | 0.83 | ||
eGFR=estimated glomerular filtration rate; ACR=urinary albumin to creatinine ratio; BMI=body mass index; PHQ-9=patient health questionnaire-9.
*Intracluster correlations (ICCs) estimated for baseline outcome using one way analysis of variance; ICC values not shown were truncated at zero.
†Intervention effect is the adjusted difference in mean change in outcome before and after intervention between study groups with 95% confidence intervals and P values calculated using marginal linear regression adjusted for baseline outcome measure, practice type, and Australian Primary Care Collaboratives (APCC) programme using generalised estimating equations with robust standard errors to adjust for clustering.
‡Intervention effect is the adjusted odds ratio with 95% confidence intervals and P values calculated using marginal logistic regression adjusted for practice type and APCC programme using generalised estimating equations with robust standard errors to adjust for clustering.
§Analysis does not adjust for clustering because estimated ICC for fitted model was negative.
¶≤2.5 mg/mmol for men and ≤3.5 mg/mmol for women; geometric mean for ACR for intervention and control groups was 1.70 and 1.81 at baseline and 1.83 and 1.88 at follow-up, respectively. Adjusted geometric mean ratio for ACR at follow-up was 1.03 (95% CI 0.82 to 1.28), P=0.82.
**≤60 mL/min per 1.73 m2; eGFR calculated using CKD-EPI equation.44
††One woman in intervention group changed from being obese at baseline to being underweight at last follow-up. She died of cancer 2.5 years after first assessed at baseline; results for body mass index, weight, and waist measures remained relatively unchanged when the woman who was terminally ill was excluded from analysis (results not shown).
Association between number of coaching sessions and biochemical, clinical, and psychosocial measures at 18 months. Means (SD) presented unless stated otherwise
| No of coaching sessions by measures | Baseline | 18 months | Difference in mean change (95% CI)* | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No | Mean (SD) | No | Mean (SD) | |||||||
| Serum HbA1c (%): | ||||||||||
| 0 | 57 | 7.44 (1.00) | 50 | 7.53 (1.04) | Reference | 0.75 | ||||
| 1-4 | 108 | 8.29 (1.42) | 101 | 8.06 (1.42) | 0.04 (−0.25 to 0.33) | |||||
| ≥5 | 70 | 7.93 (0.84) | 70 | 7.78 (1.05) | −0.05 (−0.43 to 0.32) | |||||
| Total cholesterol (mmol/L): | ||||||||||
| 0 | 58 | 4.48 (0.92) | 40 | 4.33 (0.84) | Reference | 0.05 | ||||
| 1-4 | 107 | 4.63 (1.05) | 92 | 4.33 (0.96) | 0.04 (−0.37 to 0.45) | |||||
| ≥5 | 70 | 4.36 (1.10) | 68 | 3.95 (0.95) | −0.28 (−0.64 to 0.09) | |||||
| Triglycerides (mmol/L): | ||||||||||
| 0 | 56 | 1.74 (1.36) | 37 | 1.55 (0.78) | Reference | 0.43 | ||||
| 1-4 | 101 | 1.91 (1.07) | 90 | 1.88 (0.95) | 0.16 (−0.10 to 0.41) | |||||
| ≥5 | 69 | 2.19 (2.30) | 67 | 1.93 (2.02) | 0.05 (−0.22 to 0.31) | |||||
| Low density lipoprotein cholesterol (mmol/L): | ||||||||||
| 0 | 51 | 2.54 (0.72) | 38 | 2.37 (0.72) | Reference | 0.23 | ||||
| 1-4 | 102 | 2.47 (0.93) | 82 | 2.36 (0.91) | 0.01 (−0.34 to 0.35) | |||||
| ≥5 | 65 | 2.16 (0.92) | 63 | 1.94 (0.85) | −0.21 (−0.56 to 0.15) | |||||
| High density lipoprotein cholesterol (mmol/L): | ||||||||||
| 0 | 53 | 1.26 (0.35) | 38 | 1.30 (0.37) | Reference | 0.54 | ||||
| 1-4 | 103 | 1.18 (0.32) | 83 | 1.15 (0.28) | −0.03 (−0.14 to 0.08) | |||||
| ≥5 | 66 | 1.24 (0.32) | 66 | 1.23 (0.38) | −0.06 (−0.17 to 0.06) | |||||
| Weight (kg): | ||||||||||
| 0 | 58 | 90.22 (18.58) | 36 | 88.02 (20.94) | Reference | 0.46 | ||||
| 1-4 | 107 | 90.00 (18.29) | 86 | 89.96 (18.40) | 1.44 (−1.66 to 4.54) | |||||
| ≥5 | 69 | 93.08 (21.93) | 67 | 93.20 (24.05) | 2.20 (−1.32 to 5.72) | |||||
| Waist circumference (cm): | ||||||||||
| 0 | 57 | 106.23 (15.90) | 32 | 105.02 (15.06) | Reference | 0.83 | ||||
| 1-4 | 102 | 107.99 (13.79) | 77 | 107.62 (13.31) | −0.68 (−2.88 to 1.51) | |||||
| ≥5 | 67 | 109.51 (16.54) | 66 | 109.50 (17.12) | −0.41 (−3.23 to 2.40) | |||||
| Systolic: | ||||||||||
| 0 | 58 | 140 (18) | 35 | 136 (15) | Reference | 0.14 | ||||
| 1-4 | 106 | 138 (19) | 87 | 131 (13) | −3.96 (−8.01 to 0.08) | |||||
| ≥5 | 70 | 139 (18) | 67 | 134 (14) | -2.05 (-6.77 to 2.67) | |||||
| Diastolic: | ||||||||||
| 0 | 58 | 79 (10) | 35 | 80 (10) | Reference | 0.003 | ||||
| 1-4 | 105 | 79 (10) | 86 | 75 (9) | −4.67 (−7.36 to −1.97) | |||||
| ≥5 | 70 | 78 (10) | 67 | 76 (9) | −2.51 (−5.15 to 0.14) | |||||
| Diabetes self efficacy36: | ||||||||||
| 0 | 52 | 78.90 (11.27) | 38 | 80.34 (10.19) | Reference | 0.87 | ||||
| 1-4 | 95 | 79.24 (13.90) | 75 | 81.69 (11.78) | 0.87 (−2.40 to 4.14) | |||||
| ≥5 | 55 | 77.11 (10.14) | 62 | 81.23 (10.52) | 0.29 (−3.69 to 4.27) | |||||
| Diabetes support37: | ||||||||||
| 0 | 56 | 4.37 (0.53) | 40 | 4.24 (0.49) | Reference | 0.44 | ||||
| 1-4 | 106 | 4.26 (0.46) | 81 | 4.28 (0.45) | 0.07 (−0.14 to 0.29) | |||||
| ≥5 | 67 | 4.33 (0.42) | 63 | 4.35 (0.51) | 0.13 (−0.08 to 0.34) | |||||
| Quality of life38: | ||||||||||
| 0 | 55 | 0.78 (0.19) | 40 | 0.78 (0.19) | Reference | 0.64 | ||||
| 1-4 | 102 | 0.78 (0.18) | 81 | 0.78 (0.19) | 0.01 (−0.03 to 0.06) | |||||
| ≥5 | 66 | 0.79 (0.16) | 64 | 0.81 (0.13) | 0.03 (−0.28 to 0.08) | |||||
| No (%) with major depressive syndrome (PHQ-9)39: | ||||||||||
| 0 | 52 | 1 (2) | 40 | 4 (10) | Reference† | 0.91 | ||||
| 1-4 | 98 | 9 (9) | 82 | 7 (9) | 0.67 (0.07 to 6.46) | |||||
| ≥5 | 66 | 1 (2) | 64 | 4 (6) | 0.91 (0.17 to 4.71) | |||||
PHQ-9=patient health questionnaire-9.
*Unless otherwise indicated, difference in mean change in outcome before and after intervention between each session category and reference group (no coaching sessions) with 95% confidence intervals and P value calculated using marginal linear regression adjusted for baseline outcome measure using generalised estimating equations with robust standard errors to adjust for clustering effect.
†Odds ratio for major depressive syndrome for each session category and the reference group (no coaching sessions) with 95% confidence intervals and P value calculated using marginal logistic regression adjusted for baseline outcome measure using generalised estimating equations with robust standard errors to adjust for clustering effect.